Bengaluru-based Canarys has announced the launch of Auryis, their artificial intelligence (AI)-powered, unified compliance assessment platform purpose-built for Pharma and Life Sciences. This marks a pivotal step in Canarys' evolution—from a services-led organisation to a product-led company.
In a fast-changing regulatory landscape, Auryis delivers real-time, structured, and audit-ready compliance insights across all digital content—including SOPs, clinical trial documents, training materials, and marketing assets. It intelligently maps each element to external regulations (GxP, FDA, EMA), internal standards, and custom business rules—helping organisations anticipate and mitigate non-compliance risk before it escalates.
Sheshadri Srinivas, CEO, Canarys, commented, "In today's complex regulatory environment, Pharma and Life Sciences organisations face mounting pressure—manual reviews, rapidly shifting global standards, and the costly consequences of compliance gaps that can delay approvals and impact patient safety.
